All In Biotech

Drug Trial Radar · NCT01801735

Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip

A Multicenter, Open-Label, Safety Study of Meloxicam SoluMatrix™ Capsules in Subjects With Osteoarthritis of the Knee or Hip

Last checked: Nov 19, 2026Latest source record: May 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

600

Actual

Start

Mar 2013

Primary completion

Jun 2014

Study completion Aug 2014

Sponsor

Lead sponsor
Iroko Pharmaceuticals, LLCIndustry
Sponsor type
Industry
First posted
Mar 1, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety of Meloxicam SoluMatrix Capsules for up to 52 weeks in subjects with pain due to osteoarthritis (OA) of the knee or hip

Conditions

  • Osteoarthritis

Interventions

  • Meloxicam Test CapsulesDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of Meloxicam 10 mg as Assessed by the Incidence of Adverse Events From Baseline to Week 52 or Early TerminationTime frame: Baseline to Week 52/Early Termination

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Carmichael, California

  • Site not named

    Pismo Beach, California

  • Site not named

    Milford, Connecticut

  • Site not named

    DeLand, Florida

  • Site not named

    Fleming Island, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Ormond Beach, Florida

  • Site not named

    Ponte Vedra, Florida

  • Site not named

    Newton, Kansas

  • Site not named

    Prairie Village, Kansas

  • Site not named

    Wichita, Kansas

  • Site not named

    Crestview Hills, Kentucky

  • Site not named

    Brockton, Massachusetts

  • Site not named

    Traverse City, Michigan

  • Site not named

    Troy, Michigan

  • Site not named

    Hazelwood, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Hartsdale, New York

  • Site not named

    Greensboro, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Kettering, Ohio

  • Site not named

    Duncansville, Pennsylvania

  • Site not named

    Anderson, South Carolina

  • Site not named

    Clinton, South Carolina

  • Site not named

    Austin, Texas

  • Site not named

    Plano, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Charlottesville, Virginia

  • Site not named

    Roanoke, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.